MedTechIQ_3Helix InSight Engine-Beta
Preview
Open in TheBrain
Triple Helix Discovery Engine
Triple Helix Framework
Industry
Architects: Small & Medium Size Business (SMBs), Product Development, De-Risking, Validation, Building Niche & Emerging Markets
*Architects: Infectious Disease _ AntiFungal
SCYNEXIS, Inc. (NASDAQ: SCYX)
Organization & Developments: Scynexis
Parents
SCYNEXIS, Inc. (NASDAQ: SCYX)
Children
*DEVELOPS NOVEL ANTI-INFECTIVES TARGETING UNMET THERAPEUTIC NEEDS INCLUDING LIFE-THREATENING INVASIVE FUNGAL INFECTIONS.
*Pharmaceutical company focused on the development and commercialization of novel anti-infectives to address significant unmet therapeutic needs
2017: Scynexis: This Cash-Rich $2 Biotech Stock Is A Strong Buy Before 2018 - SCYNEXIS, Inc. (NASDAQ:SCYX)
2017: SCYNEXIS: Why RBC Capital Has It As 'Outperform' With Huge Potential Upside - SCYNEXIS, Inc. (NASDAQ:SCYX)
2018: Scynexis_Revisiting This ~$2 'Lottery Ticket'_seekingalpha.com
2019: How a Chicago Woman Fell Victim to Candida Auris, a Drug-Resistant Fungus_www.nytimes.com
2019: Key Takeaways From A Follow-Up Phone Call With Scynexis CEO_seekingalpha.com
2019: Scynexis finds itself in the spotlight with a weapon that may fight a superbug that’s scaring the world to death – Endpoints News
2019: Scynexis: A Novel Antifungal Drug Against Life-Threatening Resistant Infections And Ridiculously Cheap Valuation - SCYNEXIS, Inc. (NASDAQ:SCYX)
2019: Scynexis: Updates To Thesis, Expecting Rebound In The Near Term_seekingalpha.com
2019: Scynexis’ lead drug scores in vaginal yeast infection trial – Endpoints News
2019: What Scynexis' Trial Protocol News Says About Its Market Estimate_seekingalpha.com
2020: SCYNEXIS Announces Positive Top-Line Results from its Second Pivotal Phase 3 Study (VANISH-306) of Oral Ibrexafungerp for the Treatment of Vulvovaginal Candidiasis (Vaginal Yeast Infection)
2020: Scynexis: A Promising Infectious Diseases Player For 2020_seekingalpha.com
2021: Scynexis, Inc. (NASDAQ: SCYX) announced that the FDA approved BREXAFEMME (ibrexafungerp tablets), for oral use in patients with vulvovaginal candidiasis (VVC), also known as vaginal yeast infection.
2022: Scynexis plans to cut 40% of staff and license its approved antifungal in pivot to R&D
2022: Scynexis: No Compelling Reason To Invest_ seekingalpha.com
2023: As deadly pathogen spreads, GSK throws a lifeline to Scynexis with $90M deal to market antifungal
2023: Scynexis pulls vaginal infection tablet from shelves, pauses ongoing trials on the heels of contamination risk concerns
2023: Scynexis: Stock Has Been Punished Enough: GSK Partnership, Future Revenue Potential And 2-Year Cash Runway Warrant A 'Buy'_ seekingalpha.com
2024: GSK amends commercial deal with Scynexis as antifungal recall drags into 2024
2024: Scynexis: Update Following Restructuring Of GSK Deal_seekingalpha.com
Jumps
*Key People: Scynexis
Finance & Acquisitions: Scynexis